《Lens regeneration using endogenous stem cells with gain of visual function》

  • 来源专题:绿色印刷—LED
  • 编译者: 张宗鹏
  • 发布时间:2016-04-13
  • The repair and regeneration of tissues using endogenous stem cells represents an ultimate goal in regenerative medicine. To our knowledge, human lens regeneration has not yet been demonstrated. Currently, the only treatment for cataracts, the leading cause of blindness worldwide, is to extract the cataractous lens and implant an artificial intraocular lens. However, this procedure poses notable risks of complications. Here we isolate lens epithelial stem/progenitor cells (LECs) in mammals and show that Pax6 and Bmi1 are required for LEC renewal. We design a surgical method of cataract removal that preserves endogenous LECs and achieves functional lens regeneration in rabbits and macaques, as well as in human infants with cataracts. Our method differs conceptually from current practice, as it preserves endogenous LECs and their natural environment maximally, and regenerates lenses with visual function. Our approach demonstrates a novel treatment strategy for cataracts and provides a new paradigm for tissue regeneration using endogenous stem cells.

  • 原文来源:;http://www.nature.com/nature/journal/v531/n7594/full/nature17181.html
相关报告
  • 《Aqueous Metal Oxide Inks for Modifying Electrode Work Function in Polymer Solar Cells》

    • 来源专题:绿色印刷—LED
    • 编译者:张宗鹏
    • 发布时间:2016-04-13
    • A method to prepare aqueous metal oxide inks for tuning the work function (WF) of electrodes is demonstrated. Thin films prepared from the metal oxide ink based on vanadium oxide (V2O5) nanoparticles are found to increase the WF of an indium-tin-oxide (ITO) electrode. ITO substrates modified with V2O5 films are applied as a hole selective layer (HSL) in polymer solar cells (PSCs) using a poly(3-hexylthiophene) and [6,6]-phenyl-C61 butyric acid methyl ester blend as a photoactive layer. The PSCs prepared with V2O5-modified ITO show better device performance, achieving a power conversion efficiency of 3.6%, demonstrating 15% enhancement compared to conventional ITO/poly(3,4-ethylenedioxythiophene):poly(styrenesulfonate) (PEDOT-PSS) based devices. Furthermore, ITO/V2O5-modified devices exhibit better ambient stability with 60% improvement in device lifetime than those using PEDOT:PSS as an HSL. This solution-processable and highly stable WF-modifying metal oxide film can be a potential alternative material for engineering interfaces in optoelectronic devices.
  • 《ChinaXiv,2月28日,Transplantation of ACE2- mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-02-28
    • Transplantation of ACE2- mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia 提交时间: 2020-02-28 作者: Zikuan Leng 1 ; Rongjia Zhu 2 ; Wei Hou 3 ; Yingmei Feng 3 ; Hongjian Liu 4 ; Ronghua Jin 3 ; Kunlin Jin 5 ; Robert Chunhua Zhao 1 ; 作者单位: 1.School of Life Sciences, Shanghai University; 2.Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College; 3.Beijing You’an Hospital, Capital Medical University; 4.Department of Orthopaedics, the First Affiliated Hospital of Zhengzhou University; 5.University of North Texas Health Science Center; 内容摘要 A coronavirus (HCoV-19) has caused the novel coronavirus disease (COVID-19) outbreak in Wuhan, China, Preventing and reversing the cytokine storm may be the key to save the patients with severe COVID-19 pneumonia. Mesenchymal stem cells (MSCs) have been shown to possess a comprehensive powerful immunomodulatory function. This study aims to investigate whether MSC transplantation improve the outcome of 7 enrolled patients with COVID-19 pneumonia in Beijing YouAn Hospital, China from Jan 23, 2020. to Feb 16, 2020. The clinical outcomes, as well as changes of inflammatory and immune function levels and adverse effects of 7 enrolled patients were assessed for 14 days after MSC injection. MSCs could cure or significantly improve the functional outcomes of seven patients with COVID-19 pneumonia in 14 days without observed adverse effect. *注,本文为预印本论文手稿,是未经同行评审的初步报告,其观点仅供科研同行交流,并不是结论性内容,请使用者谨慎使用.